Studying Neurocognitive Effects of Hypofractionated Stereotactic Radiotherapy in Adults With Brain Oligometastases

What this Trial Is About

Researchers are evaluating the effects of hypofractionated stereotactic radiotherapy HF-SRT on patients newly diagnosed with brain oligometastases, which means having up to three brain metastatic lesions no larger than 4 cm. The study focuses on how this precise radiation treatment, which avoids the sensitive hippocampus area, impacts neurocognitive functions and cancer progression. This observational study aims to understand cognitive outcomes and brain tumor control while addressing concerns about conventional whole-brain radiation therapys impact on memory and learning. The treatment involves delivering HF-SRT using volumetric-modulated arc therapy VMAT to target brain metastases while sparing the hippocampus. This radiotherapy is given over two weeks in five sessions, with a total dose between 3000 and 3500 cGy. Patients undergo baseline brain MRI and neurocognitive assessments before treatment. The study tracks cognitive function using seven standardized neuropsychological tests and monitors cancer progression and radiation side effects. Participants will have regular neurocognitive tests and brain imaging to assess treatment effects and cancer status for up to 24 months. The main outcome is cognitive-deterioration-free survival, measuring how long patients maintain stable neurocognitive function after treatment. Secondary outcomes include overall survival, patterns of brain cancer progression, and progression-free survival. Throughout the study, researchers will observe treatment safety, cognitive health, and tumor control in patients with good performance status.

A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT